ABCG2 and ovarian cancer: One study found no relationship between a variant ABCG2 and clinical outcome in a large mixed subtype cohort of ovarian cancer patients (n = 914)[75] while a more recent study found that a ABCG2 variant (C421A) previously linked with enhanced protein degradation and drug sensitivity[76] was associated with longer PFS in patients with advanced stage epithelial ovarian cancer treated with platinum + paclitaxel-based chemotherapy[77].